© 2026 Sinochem Nanjing Corporation,
All Right Reserved
|
HS Code |
545265 |
As an accredited 4-(4-Bromo-Phenyl)-Piperazine-1-Carboxylic Acid Tert-Butyl Ester factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Competitive 4-(4-Bromo-Phenyl)-Piperazine-1-Carboxylic Acid Tert-Butyl Ester prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Organic chemistry continues to evolve, driven by the need to create new pharmaceuticals, agrochemicals, and advanced materials. Over years in laboratory settings, it becomes clear that not all intermediates deliver the same performance and reliability. 4-(4-Bromo-Phenyl)-Piperazine-1-Carboxylic Acid Tert-Butyl Ester stands out because it brings together stability, selective reactivity, and structural versatility. Researchers who have spent countless days troubleshooting yield issues understand just how impactful the choice of intermediate can become—not only for the bottom line, but for safety and clarity of results.
This compound, often recognized by its systematic structure, merges a bromo-substituted phenyl group and piperazine backbone with a tert-butyl ester carboxyl protection. That chemical mouthful matters because each feature serves a purpose. The bromo group attached to the phenyl ring isn’t just for show; it provides a reactive site ready for Suzuki couplings or other cross-coupling reactions. The piperazine core adds rigidity and introduces a pathway familiar to medicinal chemists, offering potential for fine-tuning biological actions. The tert-butyl ester acts as a protective group, making this version especially suitable for sequences requiring deprotection steps at later stages without risking damage elsewhere in a molecule. This level of design makes the compound more than a list of atoms—it’s a strategic tool.
Years of bench work bring about a certain understanding of which building blocks actually save time and which introduce headaches. Older alternatives without the tert-butyl protected carboxyl group often fall short when the synthesis calls for late-stage functionalization. Harsh deprotection conditions can scramble delicate configurations, wasting days of effort. In practical terms, chemists appreciate that this tert-butyl ester allows deprotection under milder acidic conditions, protecting more complex molecular features downstream. You notice the difference whenever sensitive amide or heterocyclic moieties need to survive all the way through the route. It’s like using a precision wrench instead of hammering at a bolt.
Think back to the days of using simple piperazine derivatives or phenylpiperazines without the bromo functionalization. Those compounds serve basic scaffold purposes, but they close off opportunities for fine-tuned modifications. Without a bromo group on the para-phenyl ring, your choices narrow; you can't easily set up palladium-catalyzed transformations that open doors to diverse libraries. Substituents alter the electronic and steric landscape. Substituted phenylpiperazines, especially those designed for pharmaceutical research, sometimes introduce unwanted side reactions or prove unstable when scale-up comes into play. Harsh reagents required for removing less labile ester groups, like methyl or ethyl, can create purification nightmares or even scrub away fragile portions of a molecule—which is a risk anyone who’s lost a batch to column chromatography knows all too well. This tert-butyl ester sidesteps those pitfalls, offering a clean break under the right conditions.
In drug discovery, time matters. Teams pour effort into crafting molecules with precise biological activity, and a trusted intermediate can shave weeks off development timelines. 4-(4-Bromo-Phenyl)-Piperazine-1-Carboxylic Acid Tert-Butyl Ester fits as a junction point in synthesizing compounds that test for analgesic, antipsychotic, and antiviral properties. Its structure allows for quick diversification using well-mapped reactions. In practice, researchers introduce bespoke side chains at the aromatic ring with relative ease, preserving the core piperazine framework. For those who worked with earlier, less functionalized compounds, this targeted reactivity means less troubleshooting and more successful analogues per synthetic cycle. Those are tangible benefits, especially under tight deadlines typical in startup or academic settings.
It’s tempting as a young researcher to reach for whatever’s on the shelf or to stick with compounds you’ve seen in established procedures. The lesson comes after seeing productivity stall, purification layers multiply, or yields shrink because of poorly chosen intermediates. For experienced chemists, switching from basic carboxylic acids or simple esters to a tert-butyl-protected system feels like discovering a shortcut in a familiar city. The work streamlines, steps drop, and the whole workflow accelerates. I’ve seen colleagues sigh in relief when the tert-butyl group comes off smoothly while neighboring groups stay intact—especially when trying to preserve sensitive pharmacophores. It is conversions like these that foster trust in a compound’s design and manufacturing consistency.
Research can only advance with confidence in the tools used. Impurities in chemical stock can derail promising leads, introducing artifacts in bioassays or confusing structure-activity relationship data. This intermediate, manufactured under protocols that meet strict quality thresholds, tends to deliver reliable assay results. Buyers familiar with subpar batches know how a cheap intermediate can bleed time, budget, and goodwill. Availability in high purity grades aligns with the requirements of both discovery-phase research and process development, supporting the transition from milligram to larger, even pilot-plant, quantities without loss of profile.
Chemists recognize that subtleties in chemical structure affect more than reactivity—handling safety and environmental control matter as much. The tert-butyl ester often offers better handling characteristics compared to lower molecular weight analogues, which may be volatile or emit noxious odors. Labs see less loss to evaporation, fewer respiratory complaints, and smoother inventory controls when intermediates remain stable under storage and everyday use. Environmental teams appreciate the more straightforward byproduct management, especially if downstream deprotection steps consistently yield tert-butanol and harmless fragments.
Teams involved in rapid prototyping and high-throughput screening look for intermediates that fit a modular assembly approach. This compound’s combination of a reactive aryl bromide and a robust, yet cleavable, tert-butyl ester fits a menu-driven synthesis design. Each moiety on the molecule brings predictable chemistry, allowing for plug-and-play assembly of different analogues, whether the goal is receptor binding optimization or fine-tuning solubility. In my experience, research groups working on CNS-active compounds, for example, cycle through series of piperazine derivatives far more efficiently when intermediates provide broad utility rather than single-shot applications.
Every well-managed lab watches its budgets with care. An intermediate that dovetails with streamlined synthesis routes saves more than reagent costs—it conserves labor and instrumentation time. The tert-butyl-protected carboxylic acid means teams avoid repeated purification cycles and unnecessary reagent replacements. Researchers can direct energy to experimental design and data analysis, not hunting for alternative purification schemes or resynthesizing failed batches. This resource ripple touches every member of a project, from graduate student to project manager.
As compounds transition from discovery to development, regulatory scrutiny increases. Impurity profiles, scalability, and repeat batch performance surface as critical gates. A mature intermediate like 4-(4-Bromo-Phenyl)-Piperazine-1-Carboxylic Acid Tert-Butyl Ester checks many boxes left blank by less robust alternatives. The wide use of tert-butyl esters in process chemistry demonstrates their acceptance and compliance with documentation requirements. Contract manufacturers can replicate the synthetic journey at larger scales without facing the unknowns that untested intermediates introduce. As someone who’s contributed to tech transfer teams, this predictability cuts down on surprise deviations, keeps costs in check, and smooths communication with regulatory affairs.
As medicinal chemistry opens new therapeutic frontiers, especially in mental health and antiviral therapies, adaptable intermediates grow in importance. The ability to attach novel fragments or tune key physical properties often hinges on the entry point provided by a reactive site like a bromo-phenyl. This single feature expands access to chemical space, powering innovation initiatives that might otherwise stall. Many teams have pivoted toward more intricate molecular architectures, and the foundation built by reliable intermediates like this one proves essential for transforming ambitious ideas into tangible breakthroughs.
It’s easy to get lost in the optimism that surrounds new chemical entities. Seasoned teams keep a focus on practical progress. Choosing intermediates wisely supports steady, repeatable advances with every new analogue or candidate. Implementing efficient deprotection strategies and selecting reagents with known compatibility accelerates route scouting and process optimization. Teams can keep waste streams manageable, reduce workup steps, and protect project momentum. If you have ever watched a promising series grind to a halt because of one stubborn protecting group, switching to a tert-butyl ester system can deliver much-needed relief.
Research seldom follows a straight path. New hypotheses require changes in scaffold, linker, or pharmacophore. Intermediates built with function-rich sites give projects a fighting chance at maneuvering around surprises. The ease of introducing new variables at the aryl ring or selectively opening the piperazine for further modification means less time devoted to custom synthesis and more focus on answering biological or physicochemical questions. Those who regularly modify structures benefit from the mix of options provided by this intermediate, including straightforward access to new analogues through trusted coupling protocols.
Chemists have felt the pressure to adopt greener protocols, as environmental sustainability picks up steam at every level, from academic grants to industrial scale-ups. Reactions that rely on harsh acids, non-benign solvents, or complex waste streams no longer make the shortlist. The use of tert-butyl-protected intermediates aligns with the move toward less aggressive purification steps and predictable byproduct profiles. Reducing lost material from failed splits, limiting exposure to persistent organic pollutants, and simplifying solvent choices supports both safety and regulatory compliance. Over time, labs that shift toward “friendlier” intermediates see an impact on their bottom line as well as their environmental stewardship scorecards.
Years spent at the bench breed habits of discernment. Selecting an intermediate isn’t just a checkbox—it’s a calculated decision based on route complexity, side reaction history, and cumulative group experience. Labs that incorporate 4-(4-Bromo-Phenyl)-Piperazine-1-Carboxylic Acid Tert-Butyl Ester into their workflows do so because prior choices fell short, complicating scale-up or polluting analytical reads with interfering fragments. This compound’s repeatable purification, safe storage, and modular reactivity reflect the learning curve of practical chemistry. It brings value not because of a flashy label, but because research memories are shaped by the reliability or unpredictability of starting materials.
Medicinal chemists drive progress by rapidly iterating structure-activity relationships (SAR). The limits of SAR work often trace back to the flexibility and accessibility of molecular intermediates. A para-bromophenyl core, hooked to piperazine and protected with tert-butyl ester, enables multiple rounds of inventive design—enabling divergent derivatizations and parallel synthesis. Teams working on these projects see productivity rise as “dead ends” disappear and cross-coupling options multiply. For anyone invested in scaffold-hopping or property tuning, this intermediate can mean the difference between staying competitive or lagging behind.
Lab morale often swings with project velocity. Chemistry that proceeds smoothly, without unexpected snags or endless troubleshooting, energizes a team. New students and seasoned researchers alike benefit from intermediates that “just work”—minimizing frustration and maximizing learning. Over the years, watching a group shift from clunky, multipurpose esters to robust, designer intermediates like the tert-butyl ester variant creates more room for collaboration and creative effort. Researchers spend less time firefighting small but persistent issues and more time exploring blue-sky projects or designing the next generation of molecules.
Collaboration often means navigating diverse endpoints and priorities. Clear, versatile intermediates smooth these junctions—allowing sets of partners to merge custom synthetic strategies confidently. This particular chemical, enjoying widespread acceptance for both its stability and performance, brings alignment to joint ventures between industry and academia. As someone who has witnessed cross-organization friction caused by incompatible or inconsistent materials, the value of a single compound that consistently performs cannot be overstated. Researchers align more easily around shared standards, and development timelines shrink when chemists on both sides use a trusted backbone.
Regulatory expectations around record-keeping and reproducibility keep rising. Reliable intermediates simplify this landscape. Full traceability, reproducible yields, and confidence in impurity profiles take the guesswork out of documentation. For teams accustomed to auxiliary purification or rescue steps, being able to streamline batch records and support audit-readiness translates into smoother project hand-offs and lower stress. This level of reliability supports deeper transparency in publications and patent filings—key outcomes for ambitious labs and companies alike.
Emerging trends, from bioorthogonal chemistry to personalized medicine, demand ever more tailored, flexible, and function-rich intermediates. 4-(4-Bromo-Phenyl)-Piperazine-1-Carboxylic Acid Tert-Butyl Ester embodies the type of chemical that empowers pioneering work without requiring endless customized modifications. With established points of reactivity and compatibility with modern synthetic tools, its utility extends into new territory, helping researchers blaze clearer, faster trails toward drug candidates or advanced materials.
Reflecting on years of synthetic problem-solving, the focus sharpens on adopting building blocks that conserve effort, funds, and intellectual momentum. As a field, chemistry advances on the shoulders of better, smarter choices in everyday work. This intermediate, designed for real-world applications and tested against the friction points of actual research, demonstrates the next step in that evolution. The journey continues, but every effective, reliable intermediate helps shape the landscape of scientific progress, discovery, and innovation.
